AbbVie Inc.
Process for Manufacturing Pibrentasvir Active Drug Substance
Last updated:
Abstract:
The present invention relates to compositions of pibrentasvir, drug products thereof, and processes and intermediates for the preparation thereof. This invention relates to the drug product, active drug substance, intermediates, and processes of pibrentasvir, a NS5A inhibitor that is useful in the treatment of hepatitis C.
Status:
Application
Type:
Utility
Filling date:
29 Aug 2019
Issue date:
10 Jun 2021